Development of new anticancer drugs using sortase-mediated ligation

利用分选酶介导的连接开发新的抗癌药物

• 批准号: nhmrc : 1047857
• 负责人: Dr Christina Schroeder
• 金额: $ 41.23万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-new-anticancer-mediated-ligation/111975
• 关键词: Development; new; anticancer; drugs; using

There is a great need for new cancer treatments. We are developing cyclic peptides as the next generation of safe and effective cancer drugs. Cyclic peptides, unlike their linear counterparts, display high stability and oral bioavailability, as well as high solubility and negligible immune response. One of the hurdles is the cyclisation process and we aim to develop enzyme-mediated cyclisation as a convenient and cost effective method for cyclic peptide production.

对新的癌症治疗方法有很大的需求。我们正在开发环肽作为下一代安全有效的抗癌药物。环肽与其线性对应物不同，显示出高稳定性和口服生物利用度，以及高溶解度和可忽略的免疫应答。其中一个障碍是环化过程，我们的目标是开发酶介导的环化作为一种方便和成本效益的方法，用于环肽生产。